Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563053 · ClinicalTrials.gov registry record · Phase 3
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
A Phase 3 study, sponsored by Quince Therapeutics S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT03563053: Clinical Trial Phase 3 study, sponsored by Quince Therapeutics S.p.A..
NCT03563053 is a Phase 3 study that was terminated before completion, run by Quince Therapeutics S.p.A.. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03563053, a Phase 3 study, was terminated before completion, sponsored by Quince Therapeutics S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale). Exploratory Objective: To evaluate the long-term effect of EDS-EP in treating central nervous system (CNS) symptoms, as measured by the "Modified" International Cooperative Ataxia Rating Scale (mICARS), and Clinical Global Impression of severity and change (CGI-S/C).
Interventions
- COMBINATION_PRODUCT EryDex System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-06-12 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563053
The ClinicalTrials.gov registry entry for NCT03563053 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quince Therapeutics S.p.A., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EryDex System is the first listed.
NCT03563053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03563053 about?
NCT03563053 is a clinical study titled "Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study". Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale). Exploratory Objective: To evaluate the long-term effect of EDS-EP in ...
What is the current status of trial NCT03563053?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2018-06-12. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT03563053?
The interventions under investigation include: EryDex System (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03563053?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.